Allena Pharmaceuticals IPO

11/1/2017

IPO

$74,200,000

We currently expect to use the net proceeds from this offering, together with our existing cash, cash equivalents and investments, as follows: approximately $45.0 million for our planned pivotal Phase 3 clinical program of ALLN-177 for the treatment of patients with enteric hyperoxaluria, including clinical research outsourcing and drug manufacturing; approximately $3.0 million for our planned Phase 2 clinical trial of ALLN-177 in adolescents and adults with primary hyperoxaluria or severe forms of secondary hyperoxaluria, including clinical research outsourcing and drug manufacturing; approximately $3.0 million for our planned development of ALLN-346 for the treatment of patients with hyperuricemia and CKD, including preclinical proof of concept in hyperuricemia animal models, customary toxicology studies and preparation for filing of an investigational new drug application; approximately $8.0 million to fund our process validation and manufacturing batches for ALLN-177; and the remai

Publicly-held

Biopharmaceutical

1 Executive Park Dr. 202
Newton, MA 02462
USA

Allena Pharmaceuticals (Nasdaq: ALNA) develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases.